Vanguard Group Inc. Raises Position in Tempus AI, Inc. $TEM

Vanguard Group Inc. increased its stake in Tempus AI, Inc. (NASDAQ:TEM) by 22.1% during the third quarter, HoldingsChannel reports. The firm owned 9,441,607 shares of the company’s stock after acquiring an additional 1,706,837 shares during the period. Vanguard Group Inc. owned about 0.05% of Tempus AI worth $762,032,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. Global Retirement Partners LLC increased its position in Tempus AI by 29.5% in the third quarter. Global Retirement Partners LLC now owns 733 shares of the company’s stock worth $59,000 after buying an additional 167 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its position in shares of Tempus AI by 0.7% during the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 33,757 shares of the company’s stock valued at $2,145,000 after buying an additional 226 shares during the last quarter. Wealth Enhancement Advisory Services LLC grew its stake in shares of Tempus AI by 2.6% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 9,929 shares of the company’s stock worth $801,000 after acquiring an additional 248 shares during the period. PNC Financial Services Group Inc. raised its stake in Tempus AI by 6.1% in the 2nd quarter. PNC Financial Services Group Inc. now owns 5,003 shares of the company’s stock valued at $318,000 after acquiring an additional 287 shares during the period. Finally, PFG Investments LLC raised its stake in Tempus AI by 8.5% in the 3rd quarter. PFG Investments LLC now owns 3,830 shares of the company’s stock valued at $309,000 after acquiring an additional 300 shares during the period. 24.22% of the stock is owned by institutional investors.

Tempus AI News Summary

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Tempus launched a pan‑cancer HRD‑RNA algorithm intended to improve tumor detection and HRD calling — the product release is being cited as a direct catalyst for recent upside in the stock. Tempus Shares Jump On AI Cancer Tool
• Positive Sentiment: Company is rolling out new AI tools across oncology, cardiology and mental health, signaling commercialization breadth beyond sequencing and bolstering the growth narrative that investors are rewarding. AI-Driven Innovation Accelerates Tempus AI’s Expansion Across MedTech
• Positive Sentiment: Mizuho initiated coverage with an “outperform” and a $100 price target, providing a high‑profile bullish endorsement that likely supported recent buying interest. Mizuho initiation coverage
• Neutral Sentiment: Research coverage by Robert W. Baird started, increasing institutional visibility; new coverage can boost liquidity but doesn’t guarantee directional moves absent model updates. Tempus AI Research Coverage Started at Robert W. Baird
• Neutral Sentiment: Market commentary pieces and a Benzinga options deep‑dive show elevated retail/derivative interest — signals of higher short‑term volatility and active positioning rather than fundamental change. Tempus AI Options Trading: A Deep Dive
• Neutral Sentiment: Analyst and media pieces (Zacks, Forbes) debate valuation and Q4 metrics — spotlighting that Tempus trades at a premium to traditional metrics and remains unprofitable on GAAP, which frames both upside expectation and valuation risk. Is TEM Stock A Buy At $60?
• Negative Sentiment: Despite product and coverage catalysts, fundamentals (negative GAAP profitability, elevated debt/equity) and technicals (current price below both 50‑ and 200‑day moving averages) increase downside risk if sentiment fades or earnings miss expectations. Unlocking Q4 Potential of Tempus

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the stock. Morgan Stanley boosted their price target on shares of Tempus AI from $80.00 to $85.00 and gave the company an “overweight” rating in a research report on Monday, December 1st. Needham & Company LLC boosted their target price on shares of Tempus AI from $70.00 to $100.00 and gave the company a “buy” rating in a report on Wednesday, November 5th. Mizuho began coverage on Tempus AI in a research report on Thursday. They set an “outperform” rating and a $100.00 target price on the stock. HC Wainwright reduced their price target on Tempus AI from $98.00 to $89.00 and set a “buy” rating for the company in a research report on Friday, November 7th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Tempus AI in a research note on Thursday, January 22nd. Eight equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $85.92.

Insiders Place Their Bets

In other news, EVP Andrew Polovin sold 10,949 shares of the business’s stock in a transaction dated Friday, February 20th. The stock was sold at an average price of $60.31, for a total transaction of $660,334.19. Following the completion of the transaction, the executive vice president owned 126,918 shares of the company’s stock, valued at approximately $7,654,424.58. The trade was a 7.94% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO James William Rogers sold 19,966 shares of the company’s stock in a transaction that occurred on Thursday, December 11th. The stock was sold at an average price of $73.20, for a total transaction of $1,461,511.20. Following the completion of the transaction, the chief financial officer owned 111,250 shares in the company, valued at approximately $8,143,500. This trade represents a 15.22% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 596,035 shares of company stock worth $37,505,125. 26.27% of the stock is owned by corporate insiders.

Tempus AI Trading Down 2.7%

Shares of TEM stock opened at $58.37 on Monday. The company has a market capitalization of $10.38 billion, a PE ratio of -49.05 and a beta of 5.22. Tempus AI, Inc. has a 52-week low of $36.22 and a 52-week high of $104.32. The business’s fifty day moving average is $62.35 and its 200 day moving average is $73.62. The company has a debt-to-equity ratio of 2.45, a quick ratio of 3.12 and a current ratio of 3.28.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.